Wael Mohamed – författare

Translational Models of Parkinson's Disease and Related Movement Disorders focuses on cutting-edge techniques for creating and validating current Parkinson's Disease translational experimental models. Various characteristics of these models are examined, including the prion-like properties of -synuclein, mitochondrial functions connected to the PINK1-Parkin pathway/CHCHD2, the endolysosome pathway connected to LRRK2, VPS35, and ATP13A2 using cultured cells (including patient iPS cells). This book also highlights the future possibilities of introducing new models for Parkinson's Disease and related movements disorders, underscoring current advancements, pre-clinical and clinical developments, and future scope related to numerous models.

Due to the lack of secure, efficient, and patient-friendly therapies for neurodegenerative disorders, there is a rising demand for innovative approaches. Despite the limited number of nanocarriers approved for human use, they have demonstrated significant potential in preclinical and, in some instances, clinical trials. In alignment with this objective, the chapters of the book are structured to offer a comprehensive overview of recent advancements in medication and dosage form development, specifically emphasizing the nanoparticulate system for targeting the brain. This book aims to furnish readers with a thorough understanding of the clinical application of nanocarrier systems for treating neurodegenerative disorders, encompassing the latest developments, challenges, safety concerns, toxicity issues, regulatory considerations, prospects, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain will find valuable insights in this resource.

Key Features

Due to the lack of secure, efficient, and patient-friendly therapies for neurodegenerative disorders, there is a rising demand for innovative approaches. Despite the limited number of nanocarriers approved for human use, they have demonstrated significant potential in preclinical and, in some instances, clinical trials. In alignment with this objective, the chapters of the book are structured to offer a comprehensive overview of recent advancements in medication and dosage form development, specifically emphasizing the nanoparticulate system for targeting the brain. This book aims to furnish readers with a thorough understanding of the clinical application of nanocarrier systems for treating neurodegenerative disorders, encompassing the latest developments, challenges, safety concerns, toxicity issues, regulatory considerations, prospects, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain will find valuable insights in this resource.

Key Features

The increasing demand for innovative techniques arises from the lack of safe, effective, and patient-friendly therapies for neurodegenerative disorders. With this objective in mind, the chapters of the book are structured to offer a thorough insight into recent advancements in utilizing the zebrafish (ZF) as a model for studying Parkinson’s disease (PD). This book aims to present readers with a comprehensive understanding of the clinical application of the ZF model in treating PD, encompassing the latest developments, challenges, safety considerations, toxicity issues, regulatory aspects, future potential, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain stand to benefit from this resource.

Key Features

The increasing demand for innovative techniques arises from the lack of safe, effective, and patient-friendly therapies for neurodegenerative disorders. With this objective in mind, the chapters of the book are structured to offer a thorough insight into recent advancements in utilizing the zebrafish (ZF) as a model for studying Parkinson’s disease (PD). This book aims to present readers with a comprehensive understanding of the clinical application of the ZF model in treating PD, encompassing the latest developments, challenges, safety considerations, toxicity issues, regulatory aspects, future potential, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain stand to benefit from this resource.

Key Features

This book comprehensively reviews the relationship between micronutrients and brain in health and diseases. It explains the relationship between micronutrients and brain functions, neurogenesis, and cognitive functions. The book also explores the relationship between micronutrients and brain disorders including depression, epilepsy, PD, and Autism. It further explores the recent advancements in understanding the important role of micronutrients as therapeutics in various brain disorders like TBI and AD. Lastly, it presents an overview of micronutrients as neuroprotective agents along with the main principles of nutrigenomics.

This book explores the molecular mechanisms of iron hemostasis in the brain and discusses the cognitive and behavioral implications of iron deficiency. It presents the effect of iron dysregulation on neurophysiological mechanisms. The book provides an overview of iron metabolism and homeostasis at the cellular level and its regulation at the mRNA translation level. It emphasizes the importance of iron for brain development in fetal and early life in preterm infants.

Further, it presents iron metabolism as a therapeutic target for novel pharmacological treatment against neurodevelopmental diseases and neurodegenerative disorders. It discusses the role of iron deficiency in sleep disorders and offers diagnosis and treatment of iron-related CNS diseases. Finally, it relates dysregulated expression of iron-related genes in brain tumors.